A citation-based method for searching scientific literature

Robert L Hollis, Alison M Meynert, Michael Churchman, Tzyvia Rye, Melanie Mackean, Fiona Nussey, Mark J Arends, Andrew H Sims, Colin A Semple, C Simon Herrington, Charlie Gourley. BMC Cancer 2018
Times Cited: 8







List of co-cited articles
70 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
321
62

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
317
37

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
37

High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Robert L Hollis, Michael Churchman, Caroline O Michie, Tzyvia Rye, Laura Knight, Andrena McCavigan, Timothy Perren, Alistair R W Williams, W Glenn McCluggage, Richard S Kaplan,[...]. Cancer 2019
14
37

Genetic and molecular changes in ovarian cancer.
Robert L Hollis, Charlie Gourley.  2016
49
37

BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, Linda Rolnitzky, Sharon Pelles-Avraham, Ravit Geva, Martin Edward Donach, John Curtin, Akiva Novetsky, Tal Grenader,[...]. Mol Cancer Ther 2011
70
37

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
37

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
775
37

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Richard T Penson, Ricardo Villalobos Valencia, David Cibula, Nicoletta Colombo, Charles A Leath, Mariusz Bidziński, Jae-Weon Kim, Joo Hyun Nam, Radoslaw Madry, Carlos Hernández,[...]. J Clin Oncol 2020
45
37

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
554
37

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
37

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
337
37


Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
609
37

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
John R McLaughlin, Barry Rosen, Joel Moody, Tuya Pal, Isabel Fan, Patricia A Shaw, Harvey A Risch, Thomas A Sellers, Ping Sun, Steven A Narod. J Natl Cancer Inst 2013
94
25

BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
Weixing Zhao, Justin B Steinfeld, Fengshan Liang, Xiaoyong Chen, David G Maranon, Chu Jian Ma, Youngho Kwon, Timsi Rao, Weibin Wang, Chen Sheng,[...]. Nature 2017
125
25

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley,[...]. Gynecol Oncol 2017
129
25


Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.
Charlie Gourley, Caroline O Michie, Patricia Roxburgh, Timothy A Yap, Sharon Harden, Jim Paul, Kalpana Ragupathy, Radha Todd, Russell Petty, Nick Reed,[...]. J Clin Oncol 2010
64
25

BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Jing Wang Chiang, Beth Y Karlan, Llana Cass, Rae Lynn Baldwin. Gynecol Oncol 2006
88
25

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R Rebbeck, Nandita Mitra, Fei Wan, Olga M Sinilnikova, Sue Healey, Lesley McGuffog, Sylvie Mazoyer, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou,[...]. JAMA 2015
245
25

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Francisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, Julie M Cunningham, Brooke L Fridley, Melissa C Larson, Kathryn Alsop, Ed Dicks, Patricia Harrington, Susan J Ramus,[...]. Clin Cancer Res 2015
93
25

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Neil Johnson, Shawn F Johnson, Wei Yao, Yu-Chen Li, Young-Eun Choi, Andrea J Bernhardy, Yifan Wang, Marzia Capelletti, Kristopher A Sarosiek, Lisa A Moreau,[...]. Proc Natl Acad Sci U S A 2013
150
25


Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
David S P Tan, Timothy A Yap, Margaret Hutka, Patricia Roxburgh, Jooern Ang, Susana Banerjee, Ewa Grzybowska, Charlie Gourley, Martin E Gore, Stan B Kaye. Eur J Cancer 2013
18
25

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Sarah S Bernards, Kathryn P Pennington, Maria I Harrell, Kathy J Agnew, Rochelle L Garcia, Barbara M Norquist, Elizabeth M Swisher. Gynecol Oncol 2018
27
25

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
705
25

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.
Martin Köbel, Kurosh Rahimi, Peter F Rambau, Christopher Naugler, Cécile Le Page, Liliane Meunier, Manon de Ladurantaye, Sandra Lee, Samuel Leung, Ellen L Goode,[...]. Int J Gynecol Pathol 2016
94
25


Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Barbara Stanley, Robert L Hollis, Hugo Nunes, Jonathan D Towler, Xiangfei Yan, Tzyvia Rye, Carol Dawson, Melanie J Mackean, Fiona Nussey, Michael Churchman,[...]. Gynecol Oncol 2019
14
25


Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
386
25

Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Lauren C Peres, Kara L Cushing-Haugen, Martin Köbel, Holly R Harris, Andrew Berchuck, Mary Anne Rossing, Joellen M Schildkraut, Jennifer A Doherty. J Natl Cancer Inst 2019
106
25

A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Sarah F Adams, Evelyn B Marsh, Wafic Elmasri, Steffanie Halberstadt, Stephanie Vandecker, Mary D Sammel, Angela R Bradbury, Mary Daly, Beth Karlan, Stephen C Rubin. Gynecol Oncol 2011
38
25


Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Alejandro Jiménez-Sánchez, Danish Memon, Stephane Pourpe, Harini Veeraraghavan, Yanyun Li, Hebert Alberto Vargas, Michael B Gill, Kay J Park, Oliver Zivanovic, Jason Konner,[...]. Cell 2017
227
25

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
25

The molecular origin and taxonomy of mucinous ovarian carcinoma.
Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, Michael S Anglesio, George Au-Yeung, Maret Böhm,[...]. Nat Commun 2019
37
25

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
25

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015
364
25

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012
366
25

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Junko Murai, Ying Feng, Guoying K Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier. Oncotarget 2016
127
25

Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Doga C Gulhan, Jake June-Koo Lee, Giorgio E M Melloni, Isidro Cortés-Ciriano, Peter J Park. Nat Genet 2019
60
25

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Steffen Böhm, Asma Faruqi, Ian Said, Michelle Lockley, Elly Brockbank, Arjun Jeyarajah, Amanda Fitzpatrick, Darren Ennis, Thomas Dowe, Jennifer L Santos,[...]. J Clin Oncol 2015
116
25

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Euan A Stronach, James Paul, Kirsten M Timms, Elisha Hughes, Krystal Brown, Christopher Neff, Michael Perry, Alexander Gutin, Mona El-Bahrawy, Jennifer H Steel,[...]. Mol Cancer Res 2018
34
25

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
142
25

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
767
25

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Harveer Dev, Ting-Wei Will Chiang, Chloe Lescale, Inge de Krijger, Alistair G Martin, Domenic Pilger, Julia Coates, Matylda Sczaniecka-Clift, Wenming Wei, Matthias Ostermaier,[...]. Nat Cell Biol 2018
133
25

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Paul A Cohen, Aime Powell, Steffen Böhm, C Blake Gilks, Colin J R Stewart, Tarek M Meniawy, Max Bulsara, Stefanie Avril, Eleanor C Brockbank, Tjalling Bosse,[...]. Gynecol Oncol 2019
26
25

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A Margolin, Sungjoon Kim, Christopher J Wilson, Joseph Lehár, Gregory V Kryukov, Dmitriy Sonkin,[...]. Nature 2012
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.